Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Food and Drug Administration Safety and Innovation Act (FDASIA)

Food and Drug Administration Safety and Innovation Act (FDASIA)

                        FDASIA Title VII Drug Supply Chain Provisions
          FDASIA Title VII Overview
          FDASIA Section 907: Inclusion of Demographic Subgroups in Clinical Trials Home
          Regulatory Information
          Laws Enforced by FDA
          Selected Amendments to the FD&C Act
          Food and Drug Administration Safety and Innovation Act (FDASIA)
          Fact Sheet: Drug Products in Shortage in the United StatesFood and Drug Administration Safety and Innovation Act (FDASIA) Fact Sheet: Drug Products in Shortage in the United States
  
  	
    Share
    Post
    Linkedin

    Email
    PrintShortages of drugs and biologics pose a significant public health threat, delaying, and in some cases even denying, critically needed care for patients. Preventing drug shortages remains a top priority for FDA.Although FDA cannot directly affect many of the business and economic decisions that contribute to drug shortages, FDA is well positioned to play a significant role as manufacturers work to restore lost production of life-saving medications.If notified of a potential disruption in production, FDA can take a number of steps to help prevent or mitigate a shortage, including:Determine if other manufacturers are willing and able to increase productionExpedite inspections and reviews of submissionsExercise temporary enforcement discretion for new sources of medically necessary drugsWork with the manufacturer to ensure adequate investigation into the root cause of the shortageReview possible risk mitigation measures for remaining inventoryHowever, FDA’s ability to take effective action depends on the relevant manufacturer notifying FDA in a timely fashion of a disruption or possible disruption in supply.Recently, the White House and Congress have taken important and welcome steps to expand early notification of interruptions and discontinuations, enhancing FDA’s ability to address drug shortages.**Improvements Seen**Early notification from manufacturers about possible shortages, as requested in the President’s Executive Order 13588 of Oct. 31, 2011 and then codified into law in the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA), has enabled FDA to work with manufacturers to restore production of many lifesaving therapies.Since the Executive Order, there has been a 6-fold increase in notifications to FDA. These increased notifications combined with allocation of additional FDA resources have resulted in real progress in addressing shortages― FDA helped prevent 195 drug shortages in 2011 and 282 drug shortages in 2012― almost an additional 100 more since the Executive Order was signed. The total number of new shortages decreased from 251 in 2011 to 117 in 2012.**Provisions of FDASIA**Title X of FDASIA provides FDA with important new authorities that will help the Agency combat drug shortages. FDASIA:broadens the scope of the early notification provision by requiring all manufacturers of certain medically important prescription drugs to notify FDA of a permanent discontinuance or a temporary interruption of manufacturing. Prior to FDASIA, only sole manufacturers of certain drug products for serious conditions were required to notify FDA of a discontinuance of those products. FDA received notifications from other manufacturers about potential shortages of other products on a voluntary basis.allows FDA to extend, by regulation, the early notification requirement to manufacturers of biologics. A proposed rule, issued on Oct. 2, 2013 by the agency would do so.requires the FDA to issue a non-compliance letter to manufacturers who fail to comply with the drug shortage notification requirements and, if the company does not have a reasonable basis for failing to comply, to make the letter and the company’s response available to the public.directs FDA to establish a task force to develop a strategic plan on drug shortages to submit to Congress**Looking Ahead - Strategic Plan**FDA convened a task force to develop and implement a strategic plan for enhancing the agency’s responses to drug shortages, as required under FDASIA. The strategic plan was published and submitted to Congress on Oct. 2. It discusses ways to improve FDA’s response to imminent or existing shortages, as well as long-term approaches to addressing quality and manufacturing issues that are the underlying cause of most drug shortages.**For More Information**More on FDASIA, its implementation, and how the FDA works to prevent drug shortages and the Strategic Plan can be found here.**Sources:**Drug ShortagesFood and Drug Administration Safety and Innovation Act (FDASIA)

                                                                                  Content current as of:
      03/28/2018Food and Drug Administration Safety and Innovation Act (FDASIA)

          
                        FDASIA Title VII Drug Supply Chain Provisions
          FDASIA Title VII Overview
          FDASIA Section 907: Inclusion of Demographic Subgroups in Clinical Trials
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop